"2024 marked a transformative year for Teva, resulting in a second consecutive year of growth, driven by our generic products ...
Argus Research analyst Jasper Hellweg maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report) yesterday. The company’s shares ...
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...
Teva Pharmaceutical Industries Limited’s TEVA share price has dipped by 13.89%, which has investors questioning if this is ...
The company will report earnings before the open on Jan. 29 Israel-based pharmaceutical giant Teva Pharmaceutical Industries ...
Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Teva ...
Harel Insurance Investments and Financial Services Ltd. (TASE: HARL) rose 4.59% for the biggest rise on the Tel Aviv 35 Index today and Phoenix Finance (TASE: PHOE) rose 2.38%. ICL (TASE: ICL: NYSE: ...
Under the terms of the agreement, Teva will lead the commercialization of FYB203 in the designated regions, to be marketed under the brand name AHZANTIVE®3, subject to regulatory approval.
Teva Pharmaceuticals International GmbH, a subsidiary of Teva, has entered into a strategic collaboration with Klinge Biopharma GmbH and Formycon AG for the semi-exclusive commercialization of FYB203, ...
Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced that they entered into a licensing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback